Filing Flows › Indivior Pharmaceuticals (INDV) › Q3 2026 › vs Q3 2025
Indivior Pharmaceuticals (INDV) Q3 2026 vs Q3 2025 (year over year)
Indivior Pharmaceuticals's revenue rose $42.0M (+13%) from $314M in Q3 2025 to $356M in Q3 2026. Gross margin 85.7% against 73.2% (+12.4 pts).
Indivior Pharmaceuticals, Q3 2026: revenue $356M (+13% year over year), operating margin 50.6%, net earnings $137M, operating cash flow $97.0M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Gross margin | 85.7% | 73.2% | +12.4 pts |
| Operating margin | 50.6% | 13.7% | +36.9 pts |
| Net margin | 38.5% | 13.4% | +25.1 pts |
| Free cash flow margin | 23.3% | -18.8% | +42.1 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $356M | $314M | $42.0M | +13% |
| Gross profit | $305M | $230M | $75.0M | +33% |
| Cost of revenue | $51.0M | $84.0M | −$33.0M | -39% |
| Other income, net | $2.0M | −$6.0M | $8.0M | — |
| Operating profit | $180M | $43.0M | $137M | +319% |
| Operating expenses | $125M | $187M | −$62.0M | -33% |
| Pre-tax earnings | $182M | $37.0M | $145M | +392% |
| Research & development | $5.0M | $33.0M | −$28.0M | -85% |
| SG&A | $119M | $154M | −$35.0M | -23% |
| Net earnings | $137M | $42.0M | $95.0M | +226% |
| Income tax | $45.0M | −$5.0M | $50.0M | — |
| Depreciation & amortization | $1.0M | $3.0M | −$2.0M | -67% |
| Share-based compensation | $8.0M | $7.0M | $1.0M | +14% |
| Working capital & other | $49.0M | $91.0M | −$42.0M | -46% |
| Operating cash flow | $97.0M | −$39.0M | $136M | — |
| Free cash flow (OCF − capex) | $83.0M | −$59.0M | $142M | — |
| Capital expenditures | $14.0M | $20.0M | −$6.0M | -30% |
Questions
How much did Indivior Pharmaceuticals's revenue grow year over year in Q3 2026?
Indivior Pharmaceuticals's revenue rose $42.0M (+13%) from $314M in Q3 2025 to $356M in Q3 2026. Gross margin 85.7% against 73.2% (+12.4 pts).